Report #2832646

Received Mar 21, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 60 yrs
State: TX
Recovered: Unknown
Vaccinated: Feb 19, 2025
Onset: Feb 19, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEPAB	HEP A + HEP B (TWINRIX)	GLAXOSMITHKLINE BIOLOGICALS	3	324BY	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

early 3rd dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 60-year-old female patient who received HAB (Twinrix adult) (batch number 324BY, expiry date 28-SEP-2026) for prophylaxis. Previously administered products included Twinrix (Patient received first dose on 29-NOV-2024) and Twinrix (Patient received second dose on 29-DEC-2024). On 19-FEB-2025, the patient received the 3rd dose of Twinrix adult. On 19-FEB-2025, an unknown time after receiving Twinrix adult, the patient experienced drug dose administration interval too short (Verbatim: early 3rd dose). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-MAR-2025 The patient received third dose of Twinrix, earlier than the recommended interval, which led to shortening of vaccinations schedule.